Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santomasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ.

Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.

PMID:
31113804
2.

CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.

Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, Brentjens RJ.

Cancer Cell. 2019 Mar 18;35(3):473-488.e6. doi: 10.1016/j.ccell.2019.02.006.

PMID:
30889381
3.

CARs of the future.

Daniyan AF, Brentjens RJ.

Am J Hematol. 2019 May;94(S1):S55-S58. doi: 10.1002/ajh.25416. Epub 2019 Feb 25. Review.

PMID:
30680777
4.

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.

Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ.

Cell Rep. 2018 May 15;23(7):2130-2141. doi: 10.1016/j.celrep.2018.04.051.

5.

Cytokine release syndrome after radiation therapy: case report and review of the literature.

Barker CA, Kim SK, Budhu S, Matsoukas K, Daniyan AF, D'Angelo SP.

J Immunother Cancer. 2018 Jan 3;6(1):1. doi: 10.1186/s40425-017-0311-9.

6.

Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies.

Daniyan AF, Brentjens RJ.

Nat Rev Clin Oncol. 2017 Jun;14(6):333-334. doi: 10.1038/nrclinonc.2017.49. Epub 2017 Apr 11. Review. No abstract available.

7.

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.

Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ.

Leukemia. 2017 Aug;31(8):1788-1797. doi: 10.1038/leu.2016.373. Epub 2016 Dec 7.

8.

At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.

Daniyan AF, Brentjens RJ.

J Leukoc Biol. 2016 Dec;100(6):1255-1264. Epub 2016 Oct 27. Review.

Supplemental Content

Loading ...
Support Center